Skip to main content
Premium Trial:

Request an Annual Quote

Battling Pancreatic Cancer

Premium

National Foundation for Cancer Research scientist Michael Sporn is working on a new class of anti-cancer drugs for the prevention of pancreatic cancer. Sporn, who is known at NFCR as "the father of chemoprevention," and his team at Dartmouth Medical School, have designed and synthesized triterpenoids — synthetic compounds that target and inhibit biological processes like inflammation, which play a role in the formation of the disease. "Recently, the researchers demonstrated that the triterpenoids, CCDO-Me and CCDO-EA, inhibited important inflammatory molecules in pancreatic cell lines and slowed the development of the harmful effects of pancreatic cancer in laboratory models that closely resemble the disease in humans," the Foundation says. Now the researchers are working on figuring out the mechanism by which triterpenoids work, and whether they can be used with standard pancreatic cancer therapies to make them more effective.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more